Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | IDH2 | P48735 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16392915 | 0.76 | IDH1 (0.95) | IDH1IDH2 | |
| SCHEMBL13915436 | 0.74 | ALDH1A1 (0.60) | CTSKKDM4E | |
| SCHEMBL16334530 | 0.74 | CTSK (0.57) | IDH1CTSKKDM4EIDH2SYK | |
| SCHEMBL3474328 | 0.74 | IDH1 (0.50) | IDH1KDM4EIDH2KCNH2 | |
| SCHEMBL16392937 | 0.73 | IDH1 (1.00) | IDH1IDH2 | |
| SCHEMBL19068519 | 0.73 | HCRTR2 (0.46) | IDH1HCRTR1HCRTR2IDH2 | |
| SCHEMBL29632510 | 0.72 | CTSK (0.59) | CTSKKDM4ESYK | |
| SCHEMBL29632728 | 0.72 | CTSK (0.59) | CTSKKDM4ESYK | |
| SCHEMBL18760238 | 0.72 | IDH1 (0.85) | IDH1IDH2 | |
| SCHEMBL3119474 | 0.72 | MALT1 (0.88) | CTSKMALT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | IDH1 3915/4885CTSK 2112/4885HCRTR1 1/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | IDH1 3915/4885CTSK 2112/4885HCRTR1 1/4885 |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | IDH1 4133/4885CTSK 2124/4885HCRTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.